Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...
Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...
Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...
Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...
Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...
Hims & Hers Health ( HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% ...
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a ...
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Hims & Hers Health (NYSE: HIMS) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some (vicariously) bad news out of the Great State of Texas. The U.S. District Court for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results